Keyphrases
Chronic Lymphocytic Leukemia
100%
Bendamustine
100%
Hematologic
33%
Alkylating Agents
33%
Purine Analogues
33%
Monoclonal Antibody
22%
Treatment Options
22%
Remission
22%
Older Patients
11%
Newly Diagnosed
11%
Rituximab
11%
Cross-resistance
11%
Alemtuzumab
11%
Relapsed or Refractory
11%
Monotherapy
11%
B Lymphocytes
11%
Fludarabine
11%
Elderly Patients
11%
Nonhematologic
11%
Effective Treatment
11%
Salvage Treatment
11%
Heavily Pretreated
11%
Relapsed Disease
11%
Additional Treatment
11%
Cladribine
11%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Lymphatic Leukemia
100%
Bendamustine
100%
Alkylating Agent
33%
Purine Derivative
33%
Purine
33%
Diseases
22%
Monoclonal Antibody
22%
Remission
22%
Cladribine
11%
Side Effect
11%
Cross-Resistance
11%
Monotherapy
11%
Rituximab
11%
Fludarabine
11%
Alemtuzumab
11%